Lactate metabolism and epigenetic reprogramming drive c-KIT hyperactivation to mediate Gilteritinib resistance: Rationale for c-KIT degraders over kinase inhibitors
Open Access
- 11 February 2026
- journal article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (6) , 3764-3783
Abstract
No abstract availableKeywords
Funding Information
- China Postdoctoral Science Foundation (2024M751531)
- National Natural Science Foundation of China (82373134)
- National Natural Science Foundation of China (82574434)
- National Natural Science Foundation of China (82404442)
- National Natural Science Foundation of China (82270172)
- National Natural Science Foundation of China (82470167)
- National Natural Science Foundation of China (824B2114)
- Fundamental Research Funds for the Central Universities
- Shenzhen Science and Technology Innovation Program (RCYX20221008092851074)
- Shenzhen Science and Technology Innovation Program (RCBS20210706092216031)
- Shenzhen Science and Technology Innovation Program (JCYJ20220531103014031)
- Natural Science Foundation of Tianjin Municipality (25JCZDJC00170)
- Natural Science Foundation of Tianjin Municipality (24JCYBJC01990)
- Shenzhen University (2023C006)
- Nankai University (24NKSYJS09)
- Fundamental Research Funds for Central Universities of the Central South University (735-63253255)
- International Science and Technology Cooperation Programme (2022YFE0133300)
This publication has 65 references indexed in Scilit:
- Cytogenetics and genomics of acute myeloid leukemiaBest Practice & Research Clinical Haematology, 2023
- Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling PathwaysDrugs in R&D, 2023
- A phase II study of combination daunorubicin, cytarabine (Ara‐c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expressionAmerican Journal of Hematology, 2023
- Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangementAnnals of Hematology, 2021
- The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistanceCancer Cell, 2021
- Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationActa Pharmaceutica Sinica B, 2020
- Eosinophilia in acute myeloid leukemia: Overlooked and underexaminedBlood Reviews, 2019
- Gilteritinib: First Global ApprovalDrugs, 2019
- FLT3–ITD and its current role in acute myeloid leukaemiaMedical Oncology, 2017
- The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrationsInvestigational New Drugs, 2015